THE EMERGING ROLE OF BIOMARKERS IN mRCC:
Selecting Patients and Predicting Response to Treatment
FREE 1.5 CME COURSE
Available November 30, 2020 – November 30, 2022
Offered free in partnership with National Kidney Foundation, this course is a 90-minute discussion by renowned clinical experts of the growing body of research on predictive biomarkers in metastatic renal cancer.
Click to access the CME webinar:
Dr. Brian Shuch, UCLA
“Current Management of Localized RCC”
Dr. David Braun, DFCI
“Predicting Response to Immune Checkpoint Inhibition in RCC”
Dr. Hans Hammers, UTSW
“Putting It All Together: Future Role of Biomarkers in Predicting mRCC Treatment Response”
In support of improving patient care, the National Kidney Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The National Kidney Foundation designates this live activity for 1.5 AMA PRA Category 1 Credits.
This CME opportunity is provided through a partnership of KidneyCAN and the National Kidney Foundation. For additional information, please use the button below to send us an email.Contact Us